Amerikanische Gesellschaft für Hirudotherapie

Metagenomic analysis of the medicinal leech gut microbiota

Basic science published in Front Microbiol (2014)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikSicherheit & InfektionskontrolleMaltz MA et al. · Frontiers in microbiology, 2014

Abstract

There are trillions of microbes found throughout the human body and they exceed the number of eukaryotic cells by 10-fold. Metagenomic studies have revealed that the majority of these microbes are found within the gut, playing an important role in the host's digestion and nutrition. The complexity of the animal digestive tract, unculturable microbes, and the lack of genetic tools for most culturable microbes make it challenging to explore the nature of these microbial interactions within this niche. The medicinal leech, Hirudo verbana, has been shown to be a useful tool in overcoming these challenges, due to the simplicity of the microbiome and the availability of genetic tools for one of the two dominant gut symbionts, Aeromonas veronii. In this study, we utilize 16S rRNA gene pyrosequencing to further explore the microbial composition of the leech digestive tract, confirming the dominance of two taxa, the Rikenella-like bacterium and A. veronii. The deep sequencing approach revealed the presence of additional members of the microbial community that suggests the presence of a moderately complex microbial community with a richness of 36 taxa. The presence of a Proteus strain as a newly identified resident in the leech crop was confirmed using fluorescence in situ hybridization (FISH). The metagenome of this community was also pyrosequenced and the contigs were binned into the following taxonomic groups: Rikenella-like (3.1 MB), Aeromonas (4.5 MB), Proteus (2.9 MB), Clostridium (1.8 MB), Eryspelothrix (0.96 MB), Desulfovibrio (0.14 MB), and Fusobacterium (0.27 MB). Functional analyses on the leech gut symbionts were explored using the metagenomic data and MG-RAST. A comparison of the COG and KEGG categories of the leech gut metagenome to that of other animal digestive-tract microbiomes revealed that the leech digestive tract had a similar metabolic potential to the human digestive tract, supporting the usefulness of this system as a model for studying digestive-tract microbiomes. This study lays the foundation for more detailed metatranscriptomic studies and the investigation of symbiont population dynamics.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

16S rRNA pyrosequencing of Hirudo verbana gut reveals dominance of Rikenella-like and Aeromonas with 36-taxa richness.

Warum dies für die Hirudotherapie relevant ist

This study used 16S rRNA gene pyrosequencing and metagenomic analysis to characterize the gut microbiota of the medicinal leech Hirudo verbana, confirming two dominant taxa (a Rikenella-like bacterium and Aeromonas veronii) and identifying 36 taxa total, including a newly confirmed Proteus resident. The leech digestive tract metagenome showed metabolic potential similar to the human digestive tract, supporting the leech as a model for studying digestive-tract microbiomes. For ASH, this provides foundational knowledge about the symbiotic biology of medicinal leeches, though its relevance is indirect as it does not address the leech secretome or hirudotherapy applications. Caveat: this is a basic microbiology and ecology study with no direct clinical or therapeutic findings.

Zitation

Metagenomic analysis of the medicinal leech gut microbiota.

Maltz MA et al. · Frontiers in microbiology, 2014

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.